Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 14657000 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Baudhuin LM, et al. (2004) S1P3-mediated Akt activation and cross-talk with platelet-derived growth factor receptor (PDGFR). FASEB J 18, 341-3 14657000
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T308-p - Akt1 (human)
Orthologous residues
Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, ovarian cancer
 Relevant cell lines - cell types - tissues:  GI-101A (breast cell), HEY (ovarian), MEF (fibroblast) [IGF1R (mouse)], T47D (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sphingosin 1-phosphate increase
AG1296 sphingosin 1-phosphate inhibit treatment-induced increase
anti-PDGFR sphingosin 1-phosphate inhibit treatment-induced increase
PDGF increase
anti-PDGFR PDGF inhibit treatment-induced increase
AG1296 PDGF inhibit treatment-induced increase
LPA increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
IGF-1 increase
AG1478 IGF-1 inhibit treatment-induced increase
AG1024 IGF-1 inhibit treatment-induced increase

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, ovarian cancer
 Relevant cell lines - cell types - tissues:  GI-101A (breast cell), HEY (ovarian), MEF (fibroblast) [IGF1R (mouse)], T47D (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
sphingosin 1-phosphate increase
AG1296 sphingosin 1-phosphate inhibit treatment-induced increase
anti-PDGFR sphingosin 1-phosphate inhibit treatment-induced increase
PDGF increase
AG1296 PDGF inhibit treatment-induced increase
anti-PDGFR PDGF inhibit treatment-induced increase
LPA increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
IGF-1 increase
AG1478 IGF-1 inhibit treatment-induced increase
AG1024 IGF-1 inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.